russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLCrussjcardiol-2498Research ArticleВ ПОМОЩЬ ПРАКТИЧЕСКОМУ ВРАЧУSUPPORTING A PRACTITIONERПРИМЕНЕНИЕ НИТРАТОВ ДЛЯ ПРОФИЛАКТИКИ АНГИНОЗНЫХ ПРИСТУПОВ У БОЛЬНЫХ СТАБИЛЬНОЙ СТЕНОКАРДИЕЙ НАПРЯЖЕНИЯ - КАКИМ ПРЕПАРАТАМ СЛЕДУЕТ ОТДАТЬ ПРЕДПОЧТЕНИЕ?Nitrates for angina episode prevention in patients with stable effort angina pectoris: what medications to choose?СыркинА. Л.SyrkinA. L.ДобровольскийА. В.DobrovolskyA. V.Московская медицинская академия им. И. М. СеченоваRussian Federation200528022005017072Copyright © Сыркин А.Л., Добровольский А.В., 20052005Сыркин А.Л., Добровольский А.В.Syrkin A.L., Dobrovolsky A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/2498
.
.
ReferencesЛечение стабильной стенокардии. Рекомендации Европейского общества кардиологов. Еur. Heart. J. 1997; 18: 394-431.Лечение стабильной стенокардии. Рекомендации Европейского общества кардиологов. Еur. Heart. J. 1997; 18: 394-431.Hutt V., Theodor R., Pabst G. and oth. Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers. Arzneimittelforschung 1993; 43(8): 842-6.Hutt V., Theodor R., Pabst G. and oth. Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers. Arzneimittelforschung 1993; 43(8): 842-6.Abshagen U.W. Pharmacokinetics of isosorbide mononitrate. Am. J. Cardiol. 1992; 70(17): 61G-66G.Abshagen U.W. Pharmacokinetics of isosorbide mononitrate. Am. J. Cardiol. 1992; 70(17): 61G-66G.Thadani U., Whitsett T. Relationship of pharmacokinetic and pharmacodynamic properties of the organic nitrates. Clin. Pharmacokinet. 1988; 15(1): 32-43.Thadani U., Whitsett T. Relationship of pharmacokinetic and pharmacodynamic properties of the organic nitrates. Clin. Pharmacokinet. 1988; 15(1): 32-43.Chasseaud L.F. Isosorbide 5-mononitrate pharmacokinetics. Cardiology. 1987; 74 Suppl 1: 6-11Chasseaud L.F. Isosorbide 5-mononitrate pharmacokinetics. Cardiology. 1987; 74 Suppl 1: 6-11Sata H., Inoue K., Nii T., Kuroda T. Influence of diet on the single dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate. Biol. Pharm. Bull. 1997; 20(10): 1111-5.Sata H., Inoue K., Nii T., Kuroda T. Influence of diet on the single dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate. Biol. Pharm. Bull. 1997; 20(10): 1111-5.Stockis A., De Bruyn S., Deroubaix X. and oth. Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). Eur. J. Pharm. Biopharm. 2002; 53(1): 49-56.Stockis A., De Bruyn S., Deroubaix X. and oth. Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). Eur. J. Pharm. Biopharm. 2002; 53(1): 49-56.Evers J., Bonn R., Boertz A. and oth. Pharmacokinetics of isosorbide dinitrate, isosorbide-2-nitrate and isosorbide-5-nitrate in renal insufficiency after repeated oral dosage. Klin. Wochenschr. 1989; 67: 342-8.Evers J., Bonn R., Boertz A. and oth. Pharmacokinetics of isosorbide dinitrate, isosorbide-2-nitrate and isosorbide-5-nitrate in renal insufficiency after repeated oral dosage. Klin. Wochenschr. 1989; 67: 342-8.Gandini R., Cunietti E., Assereto R., et al. Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation. Arzneimittelforschung. 1987; 37(7): 836-9.Gandini R., Cunietti E., Assereto R., et al. Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation. Arzneimittelforschung. 1987; 37(7): 836-9.Heidemann R., Gracien E., Menke G., Rietbrock N. Bioavailability of delayed-action and non-delayed-action preparations of isosorbide-5-nitrate. Dtsch Med Wochenschr 1987; 112(18): 719-22.Heidemann R., Gracien E., Menke G., Rietbrock N. Bioavailability of delayed-action and non-delayed-action preparations of isosorbide-5-nitrate. Dtsch Med Wochenschr 1987; 112(18): 719-22.Waller D.G. Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrate. J. Cardiovasc. Pharmacol. 1999; 34 Suppl 2: S21-7.Waller D.G. Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrate. J. Cardiovasc. Pharmacol. 1999; 34 Suppl 2: S21-7.Thadani U. Anti-anginal and anti-ischemic efficacy of conventional and slow release formulations of isosorbide-5-mononitrate in angina pectoris. Z Kardiol 1985; 74 Suppl 4: 21-4.Thadani U. Anti-anginal and anti-ischemic efficacy of conventional and slow release formulations of isosorbide-5-mononitrate in angina pectoris. Z Kardiol 1985; 74 Suppl 4: 21-4.van Hasselt M., Weis M., Haase W. Treatment of coronary heart disease with isosorbide mononitrate ('Elantan' 20). Curr. Med. Res. Opin. 1984; 9(2): 107-12.van Hasselt M., Weis M., Haase W. Treatment of coronary heart disease with isosorbide mononitrate ('Elantan' 20). Curr. Med. Res. Opin. 1984; 9(2): 107-12.Mitrovic V., Gessner C., Hain P. and oth. Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short-and long-term therapy. Clin. Cardiol. 1991; 14(3): 209-18.Mitrovic V., Gessner C., Hain P. and oth. Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short-and long-term therapy. Clin. Cardiol. 1991; 14(3): 209-18.Seabra Gomes R., Aleixo A.M., Adao M. and oth. Comparison of the effects of a controlled-release formulation of isosorbide-5-mononitrate and conventional isosorbide dinitrate on exercise performance in men with stable angina pectoris. Am. J. Cardiol. 1990; 65(20): 1308-12.Seabra Gomes R., Aleixo A.M., Adao M. and oth. Comparison of the effects of a controlled-release formulation of isosorbide-5-mononitrate and conventional isosorbide dinitrate on exercise performance in men with stable angina pectoris. Am. J. Cardiol. 1990; 65(20): 1308-12.Hennig L., Andresen D., Hennig A. and oth. Comparison of the effect of isosorbide-5-mononitrate and isosorbide dinitrate in a slow-release form on exercise-induced myocardial ischemia. J. Clin. Pharmacol. 1991; 31(7): 636-40.Hennig L., Andresen D., Hennig A. and oth. Comparison of the effect of isosorbide-5-mononitrate and isosorbide dinitrate in a slow-release form on exercise-induced myocardial ischemia. J. Clin. Pharmacol. 1991; 31(7): 636-40.Lagioia R., Scrutinio D., Mangini S.G., et al. Efficacia e durata d'azione dell'isosorbide-5-mononitrato nel trattamento dell'angina da sforzo stabile. Confronto con l'isosorbide dinitrato a cessione ritardata. G. Ital. Cardiol. 1985; 15(3): 299-306.Lagioia R., Scrutinio D., Mangini S.G., et al. Efficacia e durata d'azione dell'isosorbide-5-mononitrato nel trattamento dell'angina da sforzo stabile. Confronto con l'isosorbide dinitrato a cessione ritardata. G. Ital. Cardiol. 1985; 15(3): 299-306.Prakash A., Markham A. Long-acting isosorbide mononitrate. Drugs 1999; 57(1): 93-9.Prakash A., Markham A. Long-acting isosorbide mononitrate. Drugs 1999; 57(1): 93-9.Herrmann H., Kuhl A., Maier-Lenz H. Der Einfluss des Dosierungszeitpunktes von Isosorbidmononitrat auf objektive und subjektive Parameter der Angina pectoris. Arzneimittelforschung. 1988; 38(5): 694-8.Herrmann H., Kuhl A., Maier-Lenz H. Der Einfluss des Dosierungszeitpunktes von Isosorbidmononitrat auf objektive und subjektive Parameter der Angina pectoris. Arzneimittelforschung. 1988; 38(5): 694-8.Лупанов А.В., Алексеева И.А., Васильева Н.Н. и др. Сравнительное изучение изосорбида ди-и мононитратов у больных ишемической болезнью сердца со стабильной стенокардией, обусловленной стенозирующим коронарным атеросклерозом. Клин. мед. 2000; 78(9): 52-5.Лупанов А.В., Алексеева И.А., Васильева Н.Н. и др. Сравнительное изучение изосорбида ди-и мононитратов у больных ишемической болезнью сердца со стабильной стенокардией, обусловленной стенозирующим коронарным атеросклерозом. Клин. мед. 2000; 78(9): 52-5.Панченко Е.П., Лагута П.С., Добровольский А.Б., Карпов Ю.А. Влияние 2-недельной терапии изосорбида 5-мононитратом на толерантность к физической нагрузке и частоту приступов стенокардии у больных со стабильной стенокардией. Кардиология 1997; 12: 10-14.Панченко Е.П., Лагута П.С., Добровольский А.Б., Карпов Ю.А. Влияние 2-недельной терапии изосорбида 5-мононитратом на толерантность к физической нагрузке и частоту приступов стенокардии у больных со стабильной стенокардией. Кардиология 1997; 12: 10-14.Parker J.О. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate. Can J Cardiol 1991; 7(3): 125-30.Parker J.О. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate. Can J Cardiol 1991; 7(3): 125-30.Neuhaus R., Johnen R., Vydra L., Solbach C. Comparative clinical trial of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate in ischaemic heart disease. Pharmatherapeutica 1986; 4(8): 486-95.Neuhaus R., Johnen R., Vydra L., Solbach C. Comparative clinical trial of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate in ischaemic heart disease. Pharmatherapeutica 1986; 4(8): 486-95.Bidoggia H. Isosorbide-5-mononitrate and isosorbide dinitrate retard in the treatment of coronary heart disease: a multi-centre study. Curr. Med. Res. Opin. 1987; 10(9): 601-11.Bidoggia H. Isosorbide-5-mononitrate and isosorbide dinitrate retard in the treatment of coronary heart disease: a multi-centre study. Curr. Med. Res. Opin. 1987; 10(9): 601-11.Gunasekara N.S., Noble S. Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris. Drugs. 1999; 57(2): 261-77.Gunasekara N.S., Noble S. Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris. Drugs. 1999; 57(2): 261-77.Ganzinger U. Influence of isosorbide-5-mononitrate on the Orcadian rhythm of angina pectoris. Arzneimittelforschung. 1992; 42(3): 307-10.Ganzinger U. Influence of isosorbide-5-mononitrate on the Orcadian rhythm of angina pectoris. Arzneimittelforschung. 1992; 42(3): 307-10.Larrat E.P. Cost-effectiveness study of nitrate therapy using a decision analysis methodology. Hosp. Formul. 1994; 29(4): 277-8, 280, 283-4 passim.Larrat E.P. Cost-effectiveness study of nitrate therapy using a decision analysis methodology. Hosp. Formul. 1994; 29(4): 277-8, 280, 283-4 passim.
The authors declare that there are no conflicts of interest present.